Evaluation of Circulating Tumor DNA as a Theranostic Marker in the Management of Glioblastomas.

Study Overview
=================
Brief Summary
-----------------
Glioblastomas (GBM) are rare tumors of poor prognosis and their treatment is based on surgery followed by radiochemotherapy. Clinical and imaging evaluation is not always straightforward: the more or less complete surgery, the pseudo-progression after radiochemotherapy, the radionecrosis, the diagnosis of the relapse and the follow-up under anti-angiogenic can pose problems Clinicians and radiologists. Accessibility to a plasma tumor molecular marker would greatly facilitate the follow-up of these patients. It is now established for many cancers that circulating tumor DNA (cTNA) has the same molecular abnormalities as those identified in the primary tumor cells. Numerous studies have shown the prognostic value and diagnosis of the exploration of cDNA.

Official Title
-----------------
Evaluation of Circulating Tumor DNA as a Theranostic Marker in the Management of Glioblastomas.

Conditions
-----------------
Glioblastoma, Molecular Disease

Intervention / Treatment
-----------------
* Other: Correlation between molecular anomalies of the primary tumor and circulating tumor DNA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with grade IV glial tumor (glioblastoma according to WHO criteria) for which an indication of surgical excision with radiochemotherapy was chosen at a specialized multidisciplinary meeting of neuro-oncology at the CHU Amiens-Picardy. Patients should: be able to be followed at the CHU of Amiens throughout their treatment, be at least 18 years of age, be informed (or trusted) of the conditions and objectives of the study, having given their free and informed consent in writing, have a life expectancy of more than 6 months, be affiliated to a social security scheme. Exclusion Criteria: Patients with recurrent tumors. Patients supported for another histology. Medical, psychological or social conditions that do not allow for proper understanding of the procedures inherent in the study. Patients under tutelage, curatorship.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Patients with glial tumor<br> | Other: Correlation between molecular anomalies of the primary tumor and circulating tumor DNA<br>* The presence of a specific abnormality initially identified on the primary tumor and which can be quantified in the cDNA during the management will allow a better follow-up of the patient.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence of a correlation between the molecular abnormalities of the primary tumor and the circulating tumor DNA |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Biopsy